Forest Labs Net Falls on Generic Competition to Lexapro

Forest Laboratories Inc., the drugmaker in a proxy battle with billionaire Carl Icahn, said first-quarter profit dropped 79 percent after its top-selling medicine, the antidepressant Lexapro, lost patent exclusivity.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.